InformationGusacitinib (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 of 5-46 nM. Gusacitinib has anti-cancer activity.
InformationGusacitinib (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 of 5-46 nM. Gusacitinib has anti-cancer activity.
InformationGusacitinib (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 of 5-46 nM. Gusacitinib has anti-cancer activity.
InformationGusacitinib (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 of 5-46 nM. Gusacitinib has anti-cancer activity.
InformationGusacitinib (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 of 5-46 nM. Gusacitinib has anti-cancer activity.
InformationGusacitinib (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 of 5-46 nM. Gusacitinib has anti-cancer activity.
InformationGusacitinib (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 of 5-46 nM. Gusacitinib has anti-cancer activity.
InformationGusacitinib (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 of 5-46 nM. Gusacitinib has anti-cancer activity.